Ovulation‐Inhibiting Effects of Dienogest in a Randomized, Dose‐Controlled Pharmacodynamic Trial of Healthy Women
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Dienogest offers pharmacological advantages for the effective treatment of endometriosis and for use in contraception and hormone replacement therapy. This pharmacodynamic study investigated the ovulation‐inhibiting effects of dienogest monotherapy in healthy women. Dienogest was administered at 0.5, 1, 2, or 3 mg daily for up to 72 days to women aged 18 to 35 years (n = 102). Ovarian activity was assessed pretreatment and during 2 treatment periods (days 0–36 and days 37–72) by the Hoogland score, based on follicle size and serum estradiol and progesterone levels. Additional hormonal parameters and endometrial thickness were assessed. Hoogland scoring indicated ovulation in all women pretreatment, decreasing to 3 of 21, 1 of 23, 0 of 20, and 0 of 23 women in the 0.5‐, 1‐, 2‐, and 3‐mg groups, respectively (per‐protocol set). Maximum serum estradiol concentrations were similar to pretreatment levels in the 0.5‐ or 1‐mg group and decreased moderately (within physiologic levels) in the 2‐ or 3‐mg group. Endometrial thickness was reduced by all dienogest doses. Hormonal changes during follow‐up indicated resumption of ovulation in most women, shortly after treatment cessation. Dienogest ≥2 mg daily provides moderate suppression of estradiol production and reliable ovulation inhibition, which reverses rapidly after treatment cessation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Strowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., & Seitz, C. (2010) · Human Reproduction · doi:10.1093/humrep/dep469 · Cited by 381 · cited 4×
“It is notable that dienogest 2 mg daily was associated with stable lum bar bone mineral density (BMD) in a recent 24week trial of women with endometriosis, whereas the com parator GnRH agonist (leuprolide acetate) induced a substantial decrease in BMD.(6) A 1year study of dienogest therapy in Japan reported no los…”
BackgroundMethodInfluentialSelf-citationHormone treatment of endometriosis: The estrogenthreshold hypothesis
Barbieri, R. L. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(92)91706-g · Cited by 335
Strowitzki, T., Faustmann, T., Gerlinger, C., & Seitz, C. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.04.002 · Cited by 227 · cited 1×
“Recent clinical studies of dienogest have included 2 trial programs, performed in Europe and Japan, which investigated the efficacy and safety of this oral medication in endometriosis.(1,5,6,12,13) These trials showed that dienogest, at the dose of 2 mg daily, offers an efficacy for pain relief that is statistically s…”
MethodSelf-citationReduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment
Petraglia, F., Hornung, D., Seitz, C., Faustmann, T., Gerlinger, C., Luisi, S., Lazzeri, L., & Strowitzki, T. (2012) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-011-1941-7 · Cited by 200
Self-citationSasagawa, S., Shimizu, Y., Kami, H., Takeuchi, T., Mita, S., Imada, K., Kato, S., & Mizuguchi, K. (2008) · Steroids · doi:10.1016/j.steroids.2007.10.003 · Cited by 177 · cited 1×
“Dienogest offers a number of pharmacological advantages relevant to its use in these indications, including high specificity for the progesterone receptor, high oral bioavailabil ity, relatively short halflife,(3,9) and rapid elimination, combined with antiandrogenic activity and no min eralocorticoid or glucocorti…”
BackgroundVercellini, P., De Giorgi, O., Oldani, S., Cortesi, I., Panazza, S., & Crosignani, P. G. (1996) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(96)70152-7 · Cited by 161 · cited 1×
“Early return to fertility is an important consideration for women who wish to conceive after successful endometriosis treatment, and this characteristic of dienogest is not shared by all other available medications.(31,32) A potential limitation of this study is the investi gation of healthy volunteers rather than pa…”
BackgroundKöhler, G., Faustmann, T. A., Gerlinger, C., Seitz, C., & Mueck, A. O. (2010) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2009.08.020 · Cited by 159
Self-citationThe pharmacological profile of dienogest
Oettel, M., Breitbarth, H., Elger, W., Gräser, T., Hübler, D., Kaufmann, G., Moore, C., Patchev, V., Römer, W., Schröder, J., et al. (1999) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625189909085259 · Cited by 61
Cited by
Strowitzki, T., Faustmann, T., Gerlinger, C., Schumacher, U., Ahlers, C., & Seitz, C. (2015) · International Journal of Women's Health · doi:10.2147/ijwh.s77202 · Cited by 120
“However, the pharmacodynamic trial in healthy women, which measured serum estradiol levels every third day, may provide a more accurate representation of the effects of dienogest 2 mg when compared with the sporadic assessments of serum estradiol levels performed in the patient trials, and readers are, therefore, refe…”
Self-citationCaruso, S., Iraci, M., Cianci, S., Vitale, S. G., Fava, V., & Cianci, A. (2019) · Journal of Pain Research · doi:10.2147/jpr.s207599 · Cited by 73
“It is interesting to note that DNG 2 mg daily provides ovulation inhibition, but ovarian activity is not completely suppressed; 25 thus it has not been approved as a contraceptive.”
Dienogest in the treatment of endometriosis
Bizzarri, N., Remorgida, V., Leone Roberti Maggiore, U., Scala, C., Tafi, E., Ghirardi, V., Salvatore, S., Candiani, M., Venturini, P. L., & Ferrero, S. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.943734 · Cited by 63
Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data
Lee, J. H., Song, J. Y., Yi, K. W., Lee, S. R., Lee, D.-Y., Shin, J.-H., Cho, S., Seo, S. K., & Kim, S. H. (2018) · Reproductive Sciences · doi:10.1177/1933719118779733 · Cited by 44
“However, DNG has been reported to directly reduce endometriotic lesion through inducing hypoestrogenic, hypergestagenic local endocrine environment.(15,34) Nevertheless, considering DNG is also a kind of progestin, there may be participants who do not exhibit tissue-direct effects by DNG, and the prevalence of DNG res…”
BackgroundLiang, B., Wu, L., Xu, H., Cheung, C. W., Fung, W. Y., Wong, S. W., & Wang, C. C. (2018) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-018-0347-9 · Cited by 41
Metadata
- Authors
- Klipping, C., Duijkers, I., Remmers, A., Faustmann, T., Zurth, C., Klein, S., & Schuett, B.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2012-11
- Volume
- 52
- Issue
- 11
- Pages
- 1704-1713
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2049648603
- Cited by
- 83
- References
- 8
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ovulation‐Inhibiting Effects of Dienogest in a Randomized, Dose‐Controlled Pharmacodynamic Trial of Healthy Women. https://app.cochat.ai/papers/10.1177/0091270011423664
- The paper
- Klipping, C., Duijkers, I., Remmers, A., Faustmann, T., Zurth, C., Klein, S., & Schuett, B. (2012). Ovulation‐Inhibiting Effects of Dienogest in a Randomized, Dose‐Controlled Pharmacodynamic Trial of Healthy Women. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270011423664
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.